Notwithstanding major improvements in treatment modalities, the prognosis of patients with glioblastoma is poor. Hypofractionated radiation therapy as an alternative of the standard 6-week regimen could be an attractive approach as an effort to prevent tumor cell repopulation and reduction the total treatment period promoting patient comfort and convenience.

Inclusion Criteria:

• Patients 18 to 70 years of age with newly diagnosed and histologically confirmed glioblastoma.
• WHO performance status of 2 or less and adequate hematologic, renal, and hepatic function.

Exclusion Criteria:

• Prior diagnosis of cancer, unless disease free for > 3 years
• Previous history of radiotherapy in the head and neck region (except initial larynx tumor - T1, T2 / N0M0).
• Specific severe, active co-morbidities
• Tumor located in the brainstem
• Presence of leptomeningeal carcinomatosis
• Multicentric tumor